Dan M Roden MD

Dan Roden was born and raised in Montreal, and received his medical degree and training in Internal Medicine from McGill University.  He then went to Vanderbilt where he trained in Clinical Pharmacology and Cardiology, and has been a faculty member there since. His initial career focus – that he has maintained – was studies of the clinical, genetic, cellular, and molecular basis of arrhythmia susceptibility and variability responses to arrhythmia therapies.  Over the last 10 years, Dr. Roden has led Vanderbilt’s broader efforts in pharmacogenomics discovery and implementation.  He directs the Vanderbilt DNA databank BioVU, and is one of the key leaders overseeing the Vanderbilt PREDICT project that is preemptively embedding pharmacogenomic variant data in the Vanderbilt electronic medical record.

Dr. Roden served as Director of the Vanderbilt Arrhythmia Service, director of the Division of Clinical Pharmacology (1992-2004), and in 2006 was named Assistant Vice-Chancellor for Personalized Medicine.  Dr. Roden has received the Leon Goldberg Young Investigator Award and the Rawls Palmer Progress in Science Award from the American Society for Clinical Pharmacology and Therapeutics and the Distinguished Scientist Award and the Douglas Zipes lectureship from the Heart Rhythm Society.  He currently serves on the Science Board of the FDA. He has been elected to membership in the American Society for Clinical Investigation and the Association of American Physicians, and fellowship in the American Association for the Advancement of Science.